These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22588603)

  • 1. Quantification of antiangiogenic and antivascular drug activity by kinetic analysis of DCE-MRI data.
    Ferl GZ; Port RE
    Clin Pharmacol Ther; 2012 Jul; 92(1):118-24. PubMed ID: 22588603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma.
    Rosen MA; Schnall MD
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):770s-776s. PubMed ID: 17255308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging.
    Padhani AR; Leach MO
    Abdom Imaging; 2005; 30(3):324-41. PubMed ID: 15688112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fundamentals of quantitative dynamic contrast-enhanced MR imaging.
    Paldino MJ; Barboriak DP
    Magn Reson Imaging Clin N Am; 2009 May; 17(2):277-89. PubMed ID: 19406359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies.
    Padhani AR; Husband JE
    Clin Radiol; 2001 Aug; 56(8):607-20. PubMed ID: 11467863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging.
    Choyke PL; Dwyer AJ; Knopp MV
    J Magn Reson Imaging; 2003 May; 17(5):509-20. PubMed ID: 12720260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment.
    Cuenod CA; Fournier L; Balvay D; Guinebretière JM
    Abdom Imaging; 2006; 31(2):188-93. PubMed ID: 16447089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker.
    Hylton N
    J Clin Oncol; 2006 Jul; 24(20):3293-8. PubMed ID: 16829653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI for assessing antivascular cancer treatments.
    Padhani AR
    Br J Radiol; 2003; 76 Spec No 1():S60-80. PubMed ID: 15456715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.
    Liu G; Rugo HS; Wilding G; McShane TM; Evelhoch JL; Ng C; Jackson E; Kelcz F; Yeh BM; Lee FT; Charnsangavej C; Park JW; Ashton EA; Steinfeldt HM; Pithavala YK; Reich SD; Herbst RS
    J Clin Oncol; 2005 Aug; 23(24):5464-73. PubMed ID: 16027440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) of atherosclerotic plaque angiogenesis.
    Calcagno C; Mani V; Ramachandran S; Fayad ZA
    Angiogenesis; 2010 Jun; 13(2):87-99. PubMed ID: 20526859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular imaging of antiangiogenic agents.
    Rehman S; Jayson GC
    Oncologist; 2005 Feb; 10(2):92-103. PubMed ID: 15709211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D dynamic contrast-enhanced MRI of rectal carcinoma at 3T: correlation with microvascular density and vascular endothelial growth factor markers of tumor angiogenesis.
    Zhang XM; Yu D; Zhang HL; Dai Y; Bi D; Liu Z; Prince MR; Li C
    J Magn Reson Imaging; 2008 Jun; 27(6):1309-16. PubMed ID: 18504761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions.
    Padhani AR
    J Magn Reson Imaging; 2002 Oct; 16(4):407-22. PubMed ID: 12353256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic contrast-enhanced magnetic resonance imaging in oncology.
    Knopp MV; Giesel FL; Marcos H; von Tengg-Kobligk H; Choyke P
    Top Magn Reson Imaging; 2001 Aug; 12(4):301-8. PubMed ID: 11687716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A method for pharmacokinetic modelling of dynamic contrast enhanced MRI studies of rapidly enhancing lesions acquired in a clinical setting.
    Radjenovic A; Ridgway JP; Smith MA
    Phys Med Biol; 2006 May; 51(9):N187-97. PubMed ID: 16625029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic gadobutrol-enhanced MRI predicts early response to antivascular but not to antiproliferation therapy in a mouse xenograft model.
    Dassler K; Scholle FD; Schütz G
    Magn Reson Med; 2014 May; 71(5):1826-33. PubMed ID: 23754607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer.
    Zahra MA; Tan LT; Priest AN; Graves MJ; Arends M; Crawford RA; Brenton JD; Lomas DJ; Sala E
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):766-73. PubMed ID: 19019563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging tumor angiogenesis: functional assessment using MDCT or MRI?
    Goh V; Padhani AR
    Abdom Imaging; 2006; 31(2):194-9. PubMed ID: 16333695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenomenological universalities: a novel tool for the analysis of dynamic contrast enhancement in magnetic resonance imaging.
    Gliozzi AS; Mazzetti S; Delsanto PP; Regge D; Stasi M
    Phys Med Biol; 2011 Feb; 56(3):573-86. PubMed ID: 21212471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.